Physician profile
Bradley C Carthon
NPI 1700907276
$30,670.90
in general payments reported to CMS, 2019-2025
14 companies · $43.25 in 2025
The $43.25 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,296 · 2020: $5,871 · 2021: $5,861 · 2022: $8,088 · 2023: $7,459 · 2024: $51.84 · 2025: $43.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,290 · Food and Beverage: $221 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,290.00 |
| Food and Beverage | $220.93 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12,359.09 | 2022-2023 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $6,688.94 | 2020-2022 | |
| Pfizer INC. | $3,608.16 | 2021-2022 | |
| Eisai INC. | $2,625.00 | 2019 | |
| Immunomedics, INC. | $2,362.50 | 2020 | |
| Merck Sharp & Dohme LLC | $2,260.87 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $714.50 | 2019-2025 | Enhertu |
| Verity Pharmaceuticals INC. | $51.84 | 2024 | Trelstar |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Carthon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.